B-intervention	0	5	Omega
I-intervention	5	6	-
I-intervention	6	7	3
I-intervention	8	13	fatty
I-intervention	14	19	acids
O	20	23	are
O	24	34	protective
O	35	42	against
B-condition	43	53	paclitaxel
I-condition	53	54	-
I-condition	54	61	induced
I-condition	62	72	peripheral
I-condition	73	83	neuropathy
O	83	84	:
O	85	86	a
O	87	97	randomized
O	98	104	double
O	104	105	-
O	105	110	blind
O	111	118	placebo
O	119	129	controlled
O	130	135	trial
O	135	136	.

O	137	143	Axonal
O	144	151	sensory
O	152	162	peripheral
O	163	173	neuropathy
O	174	176	is
O	177	180	the
O	181	186	major
O	187	191	dose
O	191	192	-
O	192	200	limiting
O	201	205	side
O	206	212	effect
O	213	215	of
O	216	226	paclitaxel
O	226	227	.

O	228	233	Omega
O	233	234	-
O	234	235	3
O	236	241	fatty
O	242	247	acids
O	248	252	have
O	253	263	beneficial
O	264	271	effects
O	272	274	on
O	275	287	neurological
O	288	297	disorders
O	298	302	from
O	303	308	their
O	309	316	effects
O	317	319	on
O	320	327	neurons
O	328	333	cells
O	334	337	and
O	338	348	inhibition
O	349	351	of
O	352	355	the
O	356	365	formation
O	366	368	of
O	369	384	proinflammatory
O	385	394	cytokines
O	395	403	involved
O	404	406	in
O	407	417	peripheral
O	418	428	neuropathy
O	428	429	.

O	430	434	This
O	435	440	study
O	441	444	was
O	445	446	a
O	447	457	randomized
O	458	464	double
O	465	470	blind
O	471	478	placebo
O	479	489	controlled
O	490	495	trial
O	496	498	to
O	499	510	investigate
O	511	514	the
O	515	523	efficacy
O	524	526	of
O	527	532	omega
O	532	533	-
O	533	534	3
O	535	540	fatty
O	541	546	acids
O	547	549	in
O	550	558	reducing
O	559	568	incidence
O	569	572	and
O	573	581	severity
O	582	584	of
O	585	595	paclitaxel
O	595	596	-
O	596	603	induced
O	604	614	peripheral
O	615	625	neuropathy
O	626	627	(
O	627	631	PIPN
O	631	632	)
O	632	633	.

O	634	642	Eligible
B-eligibility	643	651	patients
I-eligibility	652	656	with
I-eligibility	657	663	breast
I-eligibility	664	670	cancer
O	671	679	randomly
O	680	688	assigned
O	689	691	to
O	692	696	take
O	697	702	omega
O	702	703	-
O	703	704	3
O	705	710	fatty
O	711	715	acid
O	716	722	pearls
O	722	723	,
O	724	727	640
O	728	730	mg
O	731	732	t
O	732	733	.
O	733	734	i
O	734	735	.
O	735	736	d
O	737	743	during
O	744	756	chemotherapy
O	757	761	with
O	762	772	paclitaxel
O	773	776	and
O	777	780	one
O	781	786	month
O	787	792	after
O	793	796	the
O	797	800	end
O	801	803	of
O	804	807	the
O	808	817	treatment
O	818	820	or
B-control	821	828	placebo
O	828	829	.

O	830	838	Clinical
O	839	842	and
O	843	863	electrophysiological
O	864	871	studies
O	872	876	were
O	877	886	performed
O	887	893	before
O	894	897	the
O	898	903	onset
O	904	906	of
O	907	919	chemotherapy
O	920	923	and
O	924	927	one
O	928	933	month
O	934	939	after
O	940	949	cessation
O	950	952	of
O	953	960	therapy
O	961	963	to
O	964	972	evaluate
O	973	977	PIPN
O	978	983	based
O	984	986	on
O	987	988	"
O	988	995	reduced
O	996	1001	Total
O	1002	1012	Neuropathy
O	1013	1018	Score
O	1018	1019	"
O	1019	1020	.

B-iv-bin-abs	1021	1027	Twenty
I-iv-bin-abs	1028	1031	one
O	1032	1040	patients
O	1041	1042	(
B-iv-bin-percent	1042	1044	70
I-iv-bin-percent	1044	1045	%
O	1045	1046	)
O	1047	1049	of
O	1050	1053	the
O	1054	1059	group
O	1060	1066	taking
O	1067	1072	omega
O	1072	1073	-
O	1073	1074	3
O	1075	1080	fatty
O	1081	1085	acid
O	1086	1096	supplement
O	1097	1098	(
O	1098	1099	n
O	1100	1101	=
B-intervention-participants	1102	1104	30
O	1104	1105	)
O	1106	1109	did
O	1110	1113	not
O	1114	1121	develop
B-outcome	1122	1124	PN
O	1125	1130	while
O	1131	1133	it
O	1134	1137	was
B-cv-bin-percent	1138	1140	40
I-cv-bin-percent	1140	1141	.
I-cv-bin-percent	1141	1142	7
I-cv-bin-percent	1142	1143	%
O	1143	1144	(
B-cv-bin-abs	1145	1147	11
O	1148	1156	patients
O	1156	1157	)
O	1158	1160	in
O	1161	1164	the
O	1165	1172	placebo
O	1173	1178	group
O	1178	1179	(
O	1179	1180	n
O	1181	1182	=
B-control-participants	1183	1185	27
O	1185	1186	)
O	1186	1187	.

O	1188	1189	A
O	1190	1201	significant
O	1202	1212	difference
O	1213	1216	was
O	1217	1221	seen
O	1222	1224	in
B-outcome	1225	1227	PN
I-outcome	1228	1237	incidence
O	1238	1239	(
O	1239	1241	OR
O	1242	1243	=
O	1244	1245	0
O	1245	1246	.
O	1246	1247	3
O	1247	1248	,
O	1249	1250	.
O	1250	1252	95
O	1252	1253	%
O	1254	1256	CI
O	1257	1258	=
O	1259	1260	(
O	1260	1261	0
O	1261	1262	.
O	1262	1264	10
O	1264	1265	-
O	1265	1266	0
O	1266	1267	.
O	1267	1269	88
O	1269	1270	)
O	1270	1271	,
O	1272	1273	p
O	1274	1275	=
O	1276	1277	0
O	1277	1278	.
O	1278	1281	029
O	1281	1282	)
O	1282	1283	.

O	1284	1289	There
O	1290	1293	was
O	1294	1295	a
O	1296	1299	non
O	1299	1300	-
O	1300	1311	significant
O	1312	1317	trend
O	1318	1321	for
O	1322	1333	differences
O	1334	1336	of
O	1337	1341	PIPN
O	1342	1350	severity
O	1351	1358	between
O	1359	1362	the
O	1363	1366	two
O	1367	1372	study
O	1373	1379	groups
O	1380	1383	but
O	1384	1387	the
B-outcome	1388	1399	frequencies
I-outcome	1400	1402	of
I-outcome	1403	1405	PN
O	1406	1408	in
O	1409	1412	all
O	1413	1420	scoring
O	1421	1431	categories
O	1432	1436	were
O	1437	1443	higher
O	1444	1446	in
O	1447	1450	the
O	1451	1458	placebo
O	1459	1464	group
O	1465	1466	(
O	1466	1467	0
O	1467	1468	.
O	1468	1470	95
O	1470	1471	%
O	1472	1474	CI
O	1475	1476	=
O	1477	1478	(
O	1478	1479	-
O	1479	1480	2
O	1480	1481	.
O	1481	1483	06
O	1484	1485	-
O	1485	1486	0
O	1486	1487	.
O	1487	1489	02
O	1489	1490	)
O	1490	1491	,
O	1492	1493	p
O	1494	1495	=
O	1496	1497	0
O	1497	1498	.
O	1498	1501	054
O	1501	1502	)
O	1502	1503	.

O	1504	1509	Omega
O	1509	1510	-
O	1510	1511	3
O	1512	1517	fatty
O	1518	1523	acids
O	1524	1527	may
O	1528	1530	be
O	1531	1533	an
O	1534	1543	efficient
O	1544	1559	neuroprotective
O	1560	1565	agent
O	1566	1569	for
O	1570	1581	prophylaxis
O	1582	1589	against
O	1590	1594	PIPN
O	1594	1595	.

O	1596	1604	Patients
O	1605	1609	with
O	1610	1616	breast
O	1617	1623	cancer
O	1624	1628	have
O	1629	1630	a
O	1631	1637	longer
B-outcome	1638	1645	disease
I-outcome	1646	1650	free
I-outcome	1651	1659	survival
I-outcome	1660	1664	rate
O	1665	1669	with
O	1670	1673	the
O	1674	1677	aid
O	1678	1680	of
O	1681	1694	therapeutical
O	1695	1701	agents
O	1701	1702	.

O	1703	1710	Finding
O	1711	1712	a
O	1713	1716	way
O	1717	1719	to
O	1720	1725	solve
O	1726	1729	the
O	1730	1739	disabling
O	1740	1747	effects
O	1748	1750	of
O	1751	1755	PIPN
O	1756	1761	would
O	1762	1775	significantly
O	1776	1783	improve
O	1784	1787	the
O	1788	1796	patients
O	1796	1797	'
O	1798	1805	quality
O	1806	1808	of
O	1809	1813	life
O	1813	1814	.

O	1815	1819	This
O	1820	1825	trial
O	1826	1829	was
O	1830	1840	registered
O	1841	1843	at
O	1844	1858	ClinicalTrials
O	1858	1859	.
O	1859	1862	gov
O	1863	1864	(
O	1864	1875	NCT01049295
O	1875	1876	)
O	1876	1877	.
